Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nurix Therapeutics, Inc. - Common stock (NQ:NRIX)

12.69 +0.24 (+1.93%)
Streaming Delayed Price Updated: 2:04 PM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nurix Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 Next >
13 Analysts Have This To Say About Nurix Therapeutics
 
Via Benzinga
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the... 
Via MarketMinute
Breaking Down Nurix Therapeutics: 5 Analysts Share Their Views
 
Via Benzinga
Nurix Therapeutics Posts Downbeat Q3 Results, Joins Orthopediatrics, Levi Strauss And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Nurix Stock Falls After-Hours After Wider Q3 Loss; Oppenheimer Sees FDA Support For Bexo, Retail Buys The Dip
Via Stocktwits
8 Analysts Have This To Say About Nurix Therapeutics
 
Via Benzinga
Decoding 9 Analyst Evaluations For Nurix Therapeutics
 
Via Benzinga
Why Applied Digital Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Levi Strauss, USANA Health Sciences And 3 Stocks To Watch Heading Into Friday
US stock futures up, Apogee Enterprises, Levi Strauss, VolitionRX, USANA Health Sciences, Nurix Therapeutics report results. 
Via Benzinga
NURIX THERAPEUTICS INC (NASDAQ:NRIX) Misses Q3 2025 Estimates, Shares Drop
Nurix Therapeutics Q3 2025 results miss revenue and EPS estimates, triggering a stock drop. The biotech firm also announced pivotal trial plans for its lead drug candidate. 
Via Chartmill
6 Analysts Assess Nurix Therapeutics: What You Need To Know
 
Via Benzinga
The Analyst Verdict: Nurix Therapeutics In The Eyes Of 10 Experts
 
Via Benzinga
Unveiling 6 Analyst Insights On Nurix Therapeutics
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Which stocks are moving after the closing bell on Thursday?
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
A Glimpse Into The Expert Outlook On Nurix Therapeutics Through 5 Analysts
 
Via Benzinga
Amazon To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Nurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead Payments
The company also shared promising early data from its blood cancer drug bexobrutideg and said it plans to begin late-stage trials later this year. 
Via Stocktwits
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
What's going on in today's after hours session
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout
Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib. 
Via Benzinga
Breaking Down Nurix Therapeutics: 7 Analysts Share Their Views
 
Via Benzinga
Cathie Wood Buys More NVIDIA And AMD Stock As Chinese Tech Giants Stockpile Chips Amid Looming US Export Curbs
On Wednesday, April 23, 2025, Cathie Wood of Ark Invest purchased more stock of AMD and Nvidia amid looming US chip curbs against China. 
Via Benzinga
Expert Outlook: Nurix Therapeutics Through The Eyes Of 9 Analysts
 
Via Benzinga
Beyond The Numbers: 8 Analysts Discuss Nurix Therapeutics Stock
 
Via Benzinga
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
Wells Fargo To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.